vs
Akebia Therapeutics, Inc.（AKBA）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
RIGEL PHARMACEUTICALS INC的季度营收约是Akebia Therapeutics, Inc.的1.2倍（$69.8M vs $57.6M），Akebia Therapeutics, Inc.同比增速更快（23.9% vs 21.2%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs 32.9%）
Akebia Therapeutics是一家专注于肾病领域的生物制药企业，核心业务覆盖药物研发、临床试验及商业化推广全流程，主要开发针对慢性肾病相关贫血等适应症的创新疗法，面向全球市场，致力于满足肾病治疗领域未被满足的临床需求。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
AKBA vs RIGL — 直观对比
营收规模更大
RIGL
是对方的1.2倍
$57.6M
营收增速更快
AKBA
高出2.7%
21.2%
两年增速更快
RIGL
近两年复合增速
32.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $57.6M | $69.8M |
| 净利润 | — | $268.1M |
| 毛利率 | 78.2% | 91.5% |
| 营业利润率 | -14.8% | 33.2% |
| 净利率 | — | 384.0% |
| 营收同比 | 23.9% | 21.2% |
| 净利润同比 | — | 1769.2% |
| 每股收益（稀释后） | $-0.05 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AKBARIGL
| Q4 25 | $57.6M | $69.8M | ||
| Q3 25 | $58.8M | $69.5M | ||
| Q2 25 | $62.5M | $101.7M | ||
| Q1 25 | $57.3M | $53.3M | ||
| Q4 24 | $46.5M | $57.6M | ||
| Q3 24 | $37.4M | $55.3M | ||
| Q2 24 | $43.6M | $36.8M | ||
| Q1 24 | $32.6M | $29.5M |
净利润AKBARIGL
| Q4 25 | — | $268.1M | ||
| Q3 25 | $540.0K | $27.9M | ||
| Q2 25 | $247.0K | $59.6M | ||
| Q1 25 | $6.1M | $11.4M | ||
| Q4 24 | — | $14.3M | ||
| Q3 24 | $-20.0M | $12.4M | ||
| Q2 24 | $-8.6M | $-1.0M | ||
| Q1 24 | $-18.0M | $-8.2M |
毛利率AKBARIGL
| Q4 25 | 78.2% | 91.5% | ||
| Q3 25 | 84.0% | 93.2% | ||
| Q2 25 | 84.1% | 95.6% | ||
| Q1 25 | 86.7% | 91.7% | ||
| Q4 24 | 56.2% | 89.9% | ||
| Q3 24 | 62.2% | 85.5% | ||
| Q2 24 | 60.9% | 92.4% | ||
| Q1 24 | 64.4% | 93.1% |
营业利润率AKBARIGL
| Q4 25 | -14.8% | 33.2% | ||
| Q3 25 | 7.6% | 40.9% | ||
| Q2 25 | 22.6% | 60.1% | ||
| Q1 25 | 23.6% | 23.9% | ||
| Q4 24 | -30.8% | 28.9% | ||
| Q3 24 | -33.4% | 25.4% | ||
| Q2 24 | -20.0% | 1.2% | ||
| Q1 24 | -45.8% | -23.6% |
净利率AKBARIGL
| Q4 25 | — | 384.0% | ||
| Q3 25 | 0.9% | 40.2% | ||
| Q2 25 | 0.4% | 58.6% | ||
| Q1 25 | 10.7% | 21.5% | ||
| Q4 24 | — | 24.9% | ||
| Q3 24 | -53.5% | 22.5% | ||
| Q2 24 | -19.7% | -2.8% | ||
| Q1 24 | -55.2% | -27.9% |
每股收益（稀释后）AKBARIGL
| Q4 25 | $-0.05 | $14.11 | ||
| Q3 25 | $0.00 | $1.46 | ||
| Q2 25 | $0.00 | $3.28 | ||
| Q1 25 | $0.03 | $0.63 | ||
| Q4 24 | $-0.10 | $0.82 | ||
| Q3 24 | $-0.10 | $0.70 | ||
| Q2 24 | $-0.04 | $-0.06 | ||
| Q1 24 | $-0.09 | $-0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $184.8M | $155.0M |
| 总债务越低越好 | $48.3M | $52.5M |
| 股东权益账面价值 | $32.6M | $391.5M |
| 总资产 | $376.6M | $513.6M |
| 负债/权益比越低杠杆越低 | 1.48× | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资AKBARIGL
| Q4 25 | $184.8M | $155.0M | ||
| Q3 25 | $166.4M | $137.1M | ||
| Q2 25 | $137.3M | $108.4M | ||
| Q1 25 | $113.4M | $77.1M | ||
| Q4 24 | $51.9M | $77.3M | ||
| Q3 24 | $34.0M | $61.1M | ||
| Q2 24 | $39.5M | $49.1M | ||
| Q1 24 | $42.0M | $49.5M |
总债务AKBARIGL
| Q4 25 | $48.3M | $52.5M | ||
| Q3 25 | $47.6M | $60.0M | ||
| Q2 25 | $47.1M | $60.0M | ||
| Q1 25 | $46.5M | $60.0M | ||
| Q4 24 | $38.7M | $60.0M | ||
| Q3 24 | $38.4M | $60.0M | ||
| Q2 24 | $38.0M | $60.0M | ||
| Q1 24 | $30.1M | $60.0M |
股东权益AKBARIGL
| Q4 25 | $32.6M | $391.5M | ||
| Q3 25 | $41.6M | $117.6M | ||
| Q2 25 | $29.2M | $81.9M | ||
| Q1 25 | $24.6M | $18.6M | ||
| Q4 24 | $-49.2M | $3.3M | ||
| Q3 24 | $-50.4M | $-14.6M | ||
| Q2 24 | $-33.8M | $-29.9M | ||
| Q1 24 | $-27.3M | $-31.7M |
总资产AKBARIGL
| Q4 25 | $376.6M | $513.6M | ||
| Q3 25 | $364.2M | $242.5M | ||
| Q2 25 | $345.6M | $206.7M | ||
| Q1 25 | $310.2M | $176.0M | ||
| Q4 24 | $220.7M | $164.0M | ||
| Q3 24 | $207.1M | $139.4M | ||
| Q2 24 | $220.2M | $128.4M | ||
| Q1 24 | $225.5M | $126.5M |
负债/权益比AKBARIGL
| Q4 25 | 1.48× | 0.13× | ||
| Q3 25 | 1.15× | 0.51× | ||
| Q2 25 | 1.61× | 0.73× | ||
| Q1 25 | 1.89× | 3.23× | ||
| Q4 24 | — | 18.25× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $31.1M | $22.0M |
| 自由现金流经营现金流 - 资本支出 | $31.1M | — |
| 自由现金流率自由现金流/营收 | 53.9% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | 0.08× |
| 过去12个月自由现金流最近4个季度 | $67.7M | — |
8季度趋势，按日历期对齐
经营现金流AKBARIGL
| Q4 25 | $31.1M | $22.0M | ||
| Q3 25 | $28.1M | $24.0M | ||
| Q2 25 | $22.3M | $30.5M | ||
| Q1 25 | $-13.6M | $-893.0K | ||
| Q4 24 | $-4.5M | $14.5M | ||
| Q3 24 | $-6.7M | $21.7M | ||
| Q2 24 | $-10.1M | $302.0K | ||
| Q1 24 | $-19.4M | $-5.0M |
自由现金流AKBARIGL
| Q4 25 | $31.1M | — | ||
| Q3 25 | $28.0M | — | ||
| Q2 25 | $22.2M | — | ||
| Q1 25 | $-13.6M | — | ||
| Q4 24 | $-4.5M | — | ||
| Q3 24 | $-6.7M | — | ||
| Q2 24 | $-10.1M | — | ||
| Q1 24 | — | — |
自由现金流率AKBARIGL
| Q4 25 | 53.9% | — | ||
| Q3 25 | 47.7% | — | ||
| Q2 25 | 35.6% | — | ||
| Q1 25 | -23.7% | — | ||
| Q4 24 | -9.6% | — | ||
| Q3 24 | -17.9% | — | ||
| Q2 24 | -23.1% | — | ||
| Q1 24 | — | — |
资本支出强度AKBARIGL
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | 0.2% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.0% | — |
现金转化率AKBARIGL
| Q4 25 | — | 0.08× | ||
| Q3 25 | 52.05× | 0.86× | ||
| Q2 25 | 90.47× | 0.51× | ||
| Q1 25 | -2.22× | -0.08× | ||
| Q4 24 | — | 1.01× | ||
| Q3 24 | — | 1.75× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AKBA
| Auryxia | $48.1M | 84% |
| Vafseo | $6.2M | 11% |
| License Collaboration And Other Revenue | $3.3M | 6% |
RIGL
暂无分部数据
